ACSL5 and metabolic dysfunction-associated steatotic liver disease: Thus, SIRT6-mediated ACSL5 deacetylation represents a new regulatory pathway in FA metabolism, and targeting this pathway may be a promising approach for NAFLD/NASH prevention and treatment.